DGAP-News: Evotec receives clinical milestone as part of its discovery alliance with Boehringer Ingelheim
(firmenpresse) - DGAP-News: Evotec AG / Key word(s): Miscellaneous
Evotec receives clinical milestone as part of its discovery alliance
with Boehringer Ingelheim
30.09.2013 / 07:29
---------------------------------------------------------------------
Hamburg, Germany - 30 September 2013: Evotec AG (Frankfurt Stock Exchange:
EVT, TecDAX, ISIN: DE0005664809) today announced that its research alliance
with Boehringer Ingelheim has reached a milestone in September triggering
revenues of EUR 2.0 m to Evotec. The milestone was for the transition of an
oncology molecule into Phase I clinical trials.
Dr Mario Polywka, Chief Operating Officer of Evotec, commented: 'This is a
very important 19th milestone for Evotec in our collaboration with
Boehringer Ingelheim, as it represents the first oncology compound to
progress into FiM ('First-in-Man') studies. The collaboration continues to
drive value for both companies.'
ABOUT THE EVOTEC&BOEHRINGER INGELHEIM ALLIANCE
In 2004, Evotec entered into a multi-year, multi-target drug discovery
alliance with Boehringer Ingelheim to jointly identify and develop
pre-clinical development candidates for the treatment of various disease
areas including CNS, inflammation, cardiometabolic and respiratory
diseases. In 2009, the collaboration was extended for an additional four
years and the scope expanded to include oncology targets. Under the terms
of the agreement, Boehringer Ingelheim has full ownership and global
responsibility for clinical development, manufacturing and
commercialisation of the compounds identified. In return, Evotec receives
ongoing research payments and pre-clinical milestones. Furthermore, the
contract provides substantial long-term upside for Evotec through potential
payments for successful milestone achievements during clinical development
and royalties when new drugs reach the market.
ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies. We operate worldwide providing
the highest quality stand-alone and integrated drug discovery solutions,
covering all activities from target-to-clinic. The Company has established
a unique position by assembling top-class scientific experts and
integrating state-of-the-art technologies as well as substantial experience
and expertise in key therapeutic areas including neuroscience, pain,
metabolic diseases as well as oncology and inflammation. Evotec has
long-term discovery alliances with partners including Bayer, Boehringer
Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals, MedImmune/AstraZeneca
and Ono Pharmaceutical. In addition, the Company has existing development
partnerships and product candidates both in clinical and pre-clinical
development. These include partnerships with Boehringer Ingelheim,
MedImmune and Andromeda (Teva) in the field of diabetes, with Janssen
Pharmaceuticals in the field of depression and with Roche in the field of
Alzheimer's disease. For additional information please go to
www.evotec.com.
FORWARD LOOKING STATEMENTS - Information set forth in this press release
contains forward-looking statements, which involve a number of risks and
uncertainties. The forward-looking statements contained herein represent
the judgement of Evotec as of the date of this report. Such forward-looking
statements are neither promises nor guarantees, but are subject to a
variety of risks and uncertainties, many of which are beyond our control,
and which could cause actual results to differ materially from those
contemplated in these forward-looking statements. We expressly disclaim any
obligation or undertaking to release publicly any updates or revisions to
any such statements to reflect any change in our expectations or any change
in events, conditions or circumstances on which any such statement is
based.
Contact Evotec AG:
Gabriele Hansen, Head of Corporate Communications, Phone:
+49.(0)40.56081-255, gabriele.hansen(at)evotec.com
End of Corporate News
---------------------------------------------------------------------
30.09.2013 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: info(at)evotec.com
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover,
München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
232469 30.09.2013
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 30.09.2013 - 07:29 Uhr
Sprache: Deutsch
News-ID 301130
Anzahl Zeichen: 19499
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 347 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Evotec receives clinical milestone as part of its discovery alliance with Boehringer Ingelheim"
steht unter der journalistisch-redaktionellen Verantwortung von
Evotec AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
